Anocca’s purpose is to bring transformative treatments to patients in need

Anocca is a clinical-stage biotech company focused on the discovery and development of TCR-T cell therapies to treat cancer. We are dedicated to identifying precise cancer targets and engineering innovative cell therapies that selectively target tumors.

Anocca’s highly skilled team is using cutting-edge science with an unwavering commitment to innovation. We aim to help deliver the future of cancer immunotherapy.

If you are a healthcare provider seeking more information about our investigational therapies or have questions about patient enrollment in a clinical trial, please contact us at clinical.trials@anocca.com.

Clinical Trials

VIDAR-1

VIDAR-1 is a phase 1/2 master protocol for open-label, multi-centre, single-arm sub-studies, first in human clinical studies of TCR-T therapy (autologous TCR-modified T-cell Therapy) targeting mutated Kirsten rat sarcoma (mutKRAS) administered in metastatic or locally advanced Pancreatic Ductal Adenocarcinoma (PDAC) adult patients with specific mutKRAS and Human Leukocyte Antigen (HLA) genotypes. ANOC-001 is the first product within this clinical trial.

Patient information

If you are a patient and interested in participating in Anocca’s clinical trial, please speak to your treating physician. You and your healthcare provider can learn more about this trial by visiting here.